Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

4.500 -0.050 (-1.10%)
Streaming Delayed Price Updated: 10:24 AM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
From Abeona Therapeutics Inc.; Children's Hospital of Colorado
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
From AscellaHealth, LLC
Via GlobeNewswire
News headline image
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Cash resources totaled approximately $225 million as of June 30, 2025 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.